- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06145009
Time Restricted Eating, Eating Behaviors, and Cardiometabolic Risk in Emerging Adult Women
June 25, 2026 updated by: Carly R Pacanowski, University of Delaware
The purpose of this study is to assess how time restricted eating interventions impact eating behaviors, diet quality, and body composition in women ages 20-29 years.
Participants will be asked to limit all food and drinks (except water and some non-caloric beverages) to a 10-hour period during the day for four weeks.
Participants 1-36 will follow their usual eating and activity patterns for one week before starting, and follow whatever eating pattern they want for 4 weeks after finishing.
Participants 37-51 will follow their usual eating and activity patterns for one week before starting, and will not complete a follow up period.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
51
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19711
- University of Delaware
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Able to speak and read English
- Own a smartphone
- BMI ≥ 20 kg/m2
- Usual eating window ≥ 12 hours with the last eating occasion after 8pm on the majority of days
- Have at least a moderate baseline level of dietary restraint
Exclusion Criteria:
- Shift workers
- Being pregnant, nursing, or planning to become pregnant in the next 6 months
- Having a past or current eating disorder diagnosis
- Having a chronic medical condition (including diabetes, heart, kidney, or thyroid disease) or a condition that requires therapeutic diet or specified meal timing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Time Restricted Eating
Participants will limit their eating (all food and caloric beverages) to an eating window of 10 hours per day for 4 weeks.
The eating window must end by 8pm.
Water and non-caloric beverages are allowed outside of the eating window.
No other changes are required to the types or total amount of food eaten.
|
Limit food intake to 10 hours per day as described in the experimental arm section.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotional Eating
Time Frame: Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
Dutch Eating Behavior Questionnaire: Emotional Eating Subscale.
This subscale is scored from 1-5, with higher scores indicating higher emotional eating.
|
Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
|
External Eating
Time Frame: Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
Dutch Eating Behavior Questionnaire: External Eating Subscale.
This subscale is scored from 1-5, with higher scores indicating higher external eating.
|
Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
|
Eating in the Absence of Hunger
Time Frame: Participants 1-36: Baseline week, weeks 1 and 4 of intervention, weeks 1 and 4 of follow up Participants 37-51: Baseline week, weeks 1 and 4 of intervention
|
Assessed through surveys sent 5x/day asking about if food was eaten and why.
|
Participants 1-36: Baseline week, weeks 1 and 4 of intervention, weeks 1 and 4 of follow up Participants 37-51: Baseline week, weeks 1 and 4 of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diet Quality
Time Frame: Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
Healthy Eating Index, calculated from 3-day food records.
The Healthy Eating Index is scored from 0-100, with higher scores indicating higher diet quality.
|
Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
|
Body composition (total percent body fat)
Time Frame: Baseline and end of 4-week intervention (participants 1-36 only)
|
Percent body fat measured by DXA
|
Baseline and end of 4-week intervention (participants 1-36 only)
|
|
Body composition (visceral fat)
Time Frame: Baseline and end of 4-week intervention (participants 1-36 only)
|
Visceral fat measured by DXA
|
Baseline and end of 4-week intervention (participants 1-36 only)
|
|
Body weight
Time Frame: Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
Total body weight
|
Participants 1-36: 3 time points: baseline, end of 4-week intervention, end of 4-week follow up Participants 37-51: 2 time points: baseline, end of 4-week intervention
|
|
Continuous Glucose Monitoring
Time Frame: First 10 days of study, last 7 days of intervention period (added for participants 37-51, optional for participants 29-36)
|
Participants will wear a Dexcom continuous glucose monitor
|
First 10 days of study, last 7 days of intervention period (added for participants 37-51, optional for participants 29-36)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant experience
Time Frame: End of 9-week study (following 1-week baseline, 4-week intervention, and 4-week follow up, participants 1-36 only)
|
Qualitative interview to glean information on participants' subjective experience of the intervention
|
End of 9-week study (following 1-week baseline, 4-week intervention, and 4-week follow up, participants 1-36 only)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carly Pacanowski, PhD, University of Delaware
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 30, 2023
Primary Completion (Actual)
October 10, 2025
Study Completion (Actual)
October 10, 2025
Study Registration Dates
First Submitted
October 17, 2023
First Submitted That Met QC Criteria
November 17, 2023
First Posted (Actual)
November 22, 2023
Study Record Updates
Last Update Posted (Actual)
June 30, 2026
Last Update Submitted That Met QC Criteria
June 25, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2089190-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.